The one step will be an outcome one way or another in the litigation against the Jublia patents, which from an ACR perspective has been settled (ASX announcement Sep 18) with Valeant Pharmaceuticals (subsidiary of Bausch) but there must be other companies still fighting the patents.
Looking at Bausch's website it has Global sales of Jublia at circa USD 100mil
In order for any of ACR's generics to get FDA approval they need to be exactly the same as the Brand in every-way, including, method of treatment.
- Forums
- ASX - By Stock
- Why I have bought into ACR
ACR
acrux limited
Add to My Watchlist
0.00%
!
1.9¢

The one step will be an outcome one way or another in the...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
1.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $7.747M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 617000 | 1.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.0¢ | 646239 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 617000 | 0.019 |
3 | 381800 | 0.018 |
3 | 472000 | 0.017 |
1 | 66732 | 0.015 |
1 | 70000 | 0.014 |
Price($) | Vol. | No. |
---|---|---|
0.020 | 646239 | 2 |
0.021 | 177000 | 1 |
0.022 | 18000 | 1 |
0.023 | 115126 | 4 |
0.024 | 306848 | 8 |
Last trade - 09.59am 19/06/2025 (20 minute delay) ? |
Featured News
ACR (ASX) Chart |
The Watchlist
MEM
MEMPHASYS LIMITED.
Professor John Aitken, Scientific Director
Professor John Aitken
Scientific Director
Previous Video
Next Video
SPONSORED BY The Market Online